



Contact:

Robert Erwin
President
iBio, Inc.
302-355-2335
rerwin@ibioinc.com

Melody Carey
Co-President
Rx Communications, Inc.
917-322-2571
mcarey@rxir.com

FOR IMMEDIATE RELEASE

iBioPharma, Inc. Changes Its Name To iBio, Inc.

NEWARK, DE – August 14, 2009 – iBio, Inc. (OTCBB: IBPM) today announced Effective August 10, 2009, that we have changed our name from iBioPharma, Inc. to iBio, Inc. The name change was effected through a short-form merger pursuant to Section 253 of the General Corporation Law of the State of Delaware by merging a wholly-owned subsidiary (formed solely for the purpose of implementing the name change) into us. We are the surviving corporation and have amended our Certificate of Incorporation to change our name to iBio, Inc. pursuant to the Certificate of Ownership and Merger filed with the Secretary of State of the State of Delaware on August 10, 2009. Stockholder approval of the merger was not required, and our outstanding shares of common stock will not be affected by the change in name. Our board of directors also amended our amended and restated bylaws, board committee charters and code of business ethics to reflect our new name.

About iBio, Inc.

iBio, Inc. is a biotechnology company focused on developing vaccines and therapeutic proteins based upon its proprietary plant-based iBioLaunch™ Platform Technology. The Company's near-term focus is to advance an H1N1 influenza vaccine candidate to clinical trials and to establish business arrangements for use of the technology by licensees for the development and production of other products for the prevention and treatment of various infectious diseases including influenza, anthrax and human papilloma virus (HPV). In 2003, iBio entered into a research and development agreement with the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), a leading not-for-profit translational research institution, and has exclusive rights to the proprietary platform developed under the agreement for human health applications for developing vaccines and therapeutic products for a broad range of medical indications and for veterinary applications of plant-based influenza vaccines. For additional information please visit www.ibioinc.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

Statements included in this release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately

estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

#